Technology
Health
Biotechnology

Karyopharm Therapeutics

$8.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (0.36%) Today
$0.00 (0.00%) As of 4:30 PM EDT after-hours

Why Robinhood?

You can buy or sell KPTI and other stocks, options, ETFs, and crypto commission-free!

About KPTI

Karyopharm Therapeutics Inc. Common Stock, also called Karyopharm Therapeutics, is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Read More Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The firm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. It has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Employees
332
Headquarters
Newton, Massachusetts
Founded
2008
Market Cap
505.17M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.82M
High Today
$8.55
Low Today
$8.15
Open Price
$8.28
Volume
1.16M
52 Week High
$21.71
52 Week Low
$3.92

Collections

Technology
Health
Biotechnology
Therapy
Medical
Pharmaceutical
Cancer Prevention
Silver

KPTI News

ReutersJul 3

Karyopharm Therapeutics prices blood cancer treatment after FDA approval

5,061
ReutersJul 3

FDA approves Karyopharm Therapeutics' blood cancer drug

2,032

KPTI Earnings

-$1.09
-$0.93
-$0.76
-$0.60
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, Pre-Market

More KPTI News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.